Dr Sophie Merrick speaks to ecancer about patient-reported outcomes in resected renal cell carcinoma: Active monitoring vs. durvalumab and tremelimumab in the RAMPART trial.

In this trial, durvalumab plus tremelimumab improved disease-free survival in patients with resected renal cell carcinoma at intermediate/high risk of relapse.

Dr Merrick says that this quality-of-life analysis evaluated detailed patient-reported outcomes from baseline through 15 months.

At week 16, patients receiving the combination therapy experienced clinically meaningful reductions in overall health and quality of life, role function, fatigue, and sleep compared to active monitoring.

By month 15, most differences had resolved, though pain and cognitive function remained slightly worse in the treatment group.

These results highlight that short-term QoL impacts occur with durvalumab plus tremelimumab but generally improve over time, information that can inform patient discussions about balancing treatment benefits with tolerability.